Three Months of CAPOX Emerges as an Adjuvant Standard for Stage III Colon Cancer

Five-year overall survival was noninferior with 3 versus 6 months of CAPOX therapy, particularly in patients with low-risk tumors.

The prior IDEA collaboration — a prospective, pooled analysis of six international trials — provided support for the use of shorter-duration (3 vs. 6 months) adjuvant capecitabine and oxaliplatin (CAPOX) for patients with stage III colon cancer, based on noninferiority for 3-year disease-free survival (DFS; NEJM JW Oncol Hematol May 2018 and N Engl J Med 2018; 378:1177). The shorter-duration therapy substantially reduced all toxicities, including neurologic toxicity.

Investigators for IDEA now report 5-year overall survival (OS) results for the 12,835 patients on these six trials. Most patients had N1 disease (72.0%); most had low-risk, T1–3 N1 disease (58.7%); most were treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX; 60.5%);…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Three Months of CAPOX Emerges as an Adjuvant Standard for Stage III Colon Cancer

Topics

Reviewing Author